Altium Capital — Full Portfolio

Opus Genetics (formerly Ocuphire) is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies and other treatments for inherited retinal diseases (IRDs) and other retinal and refractive disorders.

BiotechDeep TechDigital Health

Co-investorsCapital Midwest FundID Ventures

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos CapitalDomain Associates+8 more

Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.

BiotechHealthtechTel Aviv

Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)Jill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)inArnon Aharon(Executive Officer)in

Co-investorsOrbiMed

eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.

BiotechDeep TechMedical Devices

Mike Curtis, Ph.D.(President & Chief Executive Officer)

Co-investorsAlta PartnersEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital

OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.

Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain

Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAmgen VenturesDroia VenturesFrazier Healthcare PartnersNovo Holdings+2 more

Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.

AI & Machine LearningBiotechDeep TechHealthtech

Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in

Co-investorsClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+5 more

Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.

BiotechHealthtechMedical DevicesNew York, US

Christopher Van Tuyl(Executive Officer)Michael Geffner(Executive Officer)inPete Salzmann(Executive Officer, Director)inJay Stout(Executive Officer)inMelanie Gloria(Executive Officer)inEva Renee Barnett(Executive Officer)

Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors.

BiotechMedical DevicesCarlsbad, US

I. Richard Garr(Executive Officer, Director)Karl Johe(Executive Officer, Director)Robert McRae(Executive Officer)inHerbert Slade(Executive Officer)J.D. Finley(Executive Officer, Director)JD Finley(Chief Executive Officer)

Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome.

BiotechHealthtechAshburn, US

Michael Myers(Executive Officer, Director)Denise Carter(Executive Officer, Director)inMICHAEL MEYERS(Executive Officer, Director)Sally Bridget Lawlor(Executive Officer)Eyal Leibovitz(Executive Officer)Shai Yarkoni(Executive Officer, Director)

Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.

BiotechDigital HealthHealthtech

David Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)Marie O'Farrell(Chief Scientific Officer)Elizabeth Rozek(Chief Legal & Administrative Officer)

Co-investorsHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)

BiotechNew York, US

Raj Mehra(Chief Executive Officer)Michael Golembiewski(Chief Financial Officer)inBRIAN DORSEY(Executive Officer)CATHERINE BOVENIZER(Executive Officer)NEIL MORTON(Executive Officer)

BoardBrian Lian(Director)

Co-investorsSanofi VenturesDolby Family Ventures